Embecta EMBC 深 沪
等待开盘 11-05 09:30:00 美东时间
6.52
+0.440
+7.24%
华盛通- 最 高6.79
- 今 开6.25
- 成交量 115.38万股
- 最 低 6.20
- 昨 收 6.08
- 总市值 3.69亿
- 52周最高 14.485
- 市盈率 静 4.03
- 换手率 2.04%
- 52周最低 2.75
- 委 比 -72.99%
- 总股本 5665.96万
- 历史最高 34.52
- 量 比 1.39
- 振 幅 9.70%
- 历史最低 2.75
- 每 手 1
- 风险率 3.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多embecta to Participate in Investor Events
Embecta Corp., a global medical supplies company advancing its legacy in insulin delivery, announced that its management will participate in two investor events: the Wells Fargo 2026 Healthcare Conference on September 9, 2026, in Boston, MA, and the J.P. Morgan 4th Annual Nashville Healthcare Conference on September 10, 2026, in Nashville, TN. The company, with approximately 2,500 employees globally, aims to improve lives through innovative solut...
08-31 21:00
Embecta declares $0.01 dividend
Embecta (EMBC) declares $0.01/share quarterly dividend, in line with previous. Forward yield 1.14% Payable Sept. 15; for shareholders of record Aug. 27; ex-div Aug. 27. See EMBC Dividend Scorecard, Yi...
08-07 19:29
Embecta Raises FY2026 Adj EPS Guidance from $1.55-$1.75 to $1.80-$1.90 vs $1.59 Est; Affirms FY2026 Sales Guidance of $1.015B-$1.035B vs $1.021B Est
Embecta (NASDAQ:EMBC) raises FY2026 Adj EPS guidance from $1.55-$1.75 to $1.80-$1.90 vs $1.59 analyst estimate. Affirms FY2026 sales outlook from $1.015 billion-$1.035 billion to $1.015 billion-$1.035 billion vs $1.021 billion estimate.
08-07 18:34
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
B of A Securities Maintains Underperform on Embecta, Lowers Price Target to $3
B of A Securities analyst Travis Steed maintains Embecta (NASDAQ:EMBC) with a Underperform and lowers the price target from $11 to $3.
05-19 01:44
Embecta Completes Owen Mumford Acquisition to Expand Devices
An announcement from Embecta Corporation ( ($EMBC) ) is now available. On May 1...
05-15 21:52
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
Mizuho Maintains Neutral on Embecta, Lowers Price Target to $5
Mizuho analyst Anthony Petrone maintains Embecta (NASDAQ:EMBC) with a Neutral and lowers the price target from $12 to $5.
05-06 21:30
BTIG Downgrades Embecta to Neutral
BTIG analyst Marie Thibault downgrades Embecta (NASDAQ:EMBC) from Buy to Neutral.
05-06 17:34
